Scorpius Ventures

Too many promising biologic candidates are stalled without critical early-stage funding. Grant funding often falls short of the capital needed for pre-clinical and phase 1 manufacturing, but dilutive capital is hard to secure without positive early-stage data. 

Scorpius Ventures offers a hybrid model for capital-efficient access to cGMP manufacturing, process development, and analytical services for early-stage biotechs through in-kind equity investment.

• Collaborate with a U.S.-owned, U.S.-operated, and U.S.-financed biologics CDMO

• Leverage Scorpius' expertise in drug substance manufacturing to assist with additional fundraising for continued clinical development 

• Flexible program supporting both mammalian and microbial programs

Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing services for protein modalities. Our facility in San Antonio, Texas specializes in working with emerging biotechs and academic researchers. Clients benefit from decades of expertise taking large molecule drugs to market and can rely on Scorpius to offer: Quality, Speed, Flexibility, & Responsiveness. Our capabilities include:

• Up to 500-L scale for mammalian-based products
• Up to 200-L scale for microbial-based products
• On-site process and analytical development

Submit our interest form. Scorpius will contact potential partners for Scorpius Ventures on a rolling basis.